- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05036408
Cancer Pain Rehabilitation Program to Reduce Pain Related Distress, and Reliance of Pain Medication Through Multimodal Nonpharmacological Solutions
Cancer Pain Rehabilitation Program in Cancer Survivorship Feasibility Study
Study Overview
Status
Intervention / Treatment
Detailed Description
PRIMARY OBJECTIVE:
I. To test the feasibility of an interdisciplinary functional restoration program in cancer survivors with chronic pain and restoring physical function.
EXPLORATORY OBJECTIVE:
I. To explore the preliminary effect of functional restoration program (FRP) in restoring physical function and reducing pain which ultimately decreases opioid consumption.
OUTLINE:
Patients participate in the cancer pain rehabilitation program for 6 weeks, including educational sessions over 2 hours once weekly, group psychological interventions, group physical therapy, and 1:1 physical and occupational therapy treatment per the patient's treatment plan. Patients may also undergo osteopathic manual treatments per physical and occupational therapy assessments.
After completion of study intervention, patients are followed up at 3 months.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
California
-
Duarte, California, United States, 91010
- City of Hope Medical Center
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- This study will be conducted in those with history of cancer in remission or with stable disease living with chronic pain greater than 6 months in duration
- Cancer survivors or stable indolent cancer patients ages 18 or older living with chronic pain
- All subjects must have the ability to understand and the willingness to sign a written informed consent
- Patients are required to have access to a computer with a camera and a reliable internet connection. The education lectures and psychotherapy group components of the program are facilitated via online Health Insurance Portability and Accountability Act (HIPPA) compliant platform
- Eligible participants will be able to read and write and speak English and be motivated and able to commit to attending six consecutive weekly group and individual sessions
Exclusion Criteria:
Patients who are less than the age of 18 or have active problems with addiction will be excluded:
- Those identified with illicit substance abuse or addiction will be referred to an addiction specialist or medication assisted treatment program through our resource coordinator
- "Active substance abuse" exclusion was defined using the Diagnostic and Statistical Manual of Mental Disorders, 5th Edition (DSM-V) Criteria which is the gold standard for diagnosing substance use disorders is a cluster of cognitive, behavioral and physiological symptoms indicated that the individual continues using the substance despite significant substance related problems
The substances that were considered are listed below:
- Alcohol
- Cannabis
- Hallucinogens
- Inhalants
- Opioids
- Sedatives (hypnotics or anxiolytics)
- Stimulants
- Overall, the diagnosis was based on pathological patterns of behaviors related to the use of the substance. Criteria that fit with overall groupings include impaired control, social impairment, risky use, and pharmacological criteria
Impaired control
- The individual may express overall desire to cut down or regulate substance use and may report multiple unsuccessful efforts to decrease or discontinue use
- The individual may spend a great deal of time obtaining the substance, using the substance, or recovering from its affects
- The individual's daily activities revolve around the substance in some instances of more severe substance use disorder
- Craving is manifested by intense desire or urge for the drug that may occur at any time
Social impairment
- Recurrent substance use may result in failure to fulfill major role obligations at work, school, or home
- The individual may continue substance use despite having persistent or recurrent social or interpersonal problems caused or exacerbated by the effects of the substance
- Important social, occupational, or recreational activities may be given up or reduced because of substance use
- The individual may withdraw from family activities and hobbies in order to use the substance
Risky use
- Recurrent use in situations in which it is physically hazardous
- The individual may continue substance use despite knowledge of having persistent or recurrent physical or psychological problem that is likely to have been caused or exacerbated by the substance
Pharmacologic criteria
- Tolerance is signaled by requiring a markedly increased dose of substance to achieve the desired effect or markedly reduced effect when the usual dose is consumed
- Withdrawal is a syndrome that occurs when blood or tissue concentrations of a substance decline in an individual who had maintained a prolonged heavy use of the substance
After developing withdrawal symptoms, the individual is likely to consume the substance to relieve the symptoms
- Symptoms of tolerance or withdrawal occurring during appropriate medication treatment with prescribed medications are specifically not counted. However, prescription medications can be used inappropriately based on criteria above and substance use disorder can be correctly diagnosed when there are other symptoms of compulsive and drug seeking behavior
Substance use disorders occur in a broad range of severity from mild to severe with severity based on number of symptom criteria endorsed.
Mild
- Presence of 2-3 symptoms
Moderate
- Presence of 4-5 symptoms
Severe
- Presence of 6-7 symptoms
- For our research purposes, our exclusion criteria included any individual who met criteria for mild, moderate, and severe substance use disorder
- Those with severe cognitive or psychiatric impairments that preclude participation in group sessions will be excluded
- Patients should not have any uncontrolled illness of any kind including ongoing or active infection
- Subjects, who are not be able to comply with the safety monitoring requirements of the study. Those who miss more than half the sessions will be considered to not have completed the program
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Supportive Care
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: Supportive care (cancer pain rehabilitation program)
Patients participate in the cancer pain rehabilitation program for 6 weeks, including educational sessions over 2 hours once weekly, group psychological interventions, group physical therapy, and 1:1 physical and occupational therapy treatment per the patient's treatment plan.
Patients may also undergo osteopathic manual treatments per physical and occupational therapy assessments.
|
Ancillary studies
Participate in group psychological intervention
Attend educational session
Other Names:
Undergo osteopathic manual treatments
Other Names:
Participate in occupational therapy
Other Names:
Participate in physical activity
Participate in physical therapy
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Feasibility of Functional Restoration Program
Time Frame: 24 months from the intervention date
|
Feasibility of the program will be determined by the proportion of referred eligible cancer survivors enrolled into the program (at least 50% who are eligible enroll) and the proportion of enrolled patients completed at least half of the intervention.
|
24 months from the intervention date
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Preliminary effect of the Functional Restoration Program in reducing pain (NSR)
Time Frame: Pre-intervention , End of intervention (6 weeks), 3 months post-intervention
|
Pain Numerical Rating Scale (NSR) score: patients are asked to circle the number between 0 and 10, zero usually represents 'no pain at all' whereas the upper limit 10 represents 'the worst pain ever possible'.
|
Pre-intervention , End of intervention (6 weeks), 3 months post-intervention
|
|
Preliminary effect of the Functional Restoration Program in reducing pain (PSEQ)
Time Frame: Pre-intervention, End of intervention (6 weeks), 3 months post-intervention
|
The Pain Self-Efficacy Questionnaire (PSEQ) score: the PSEQ is a 10-item questionnaire, developed to assess the confidence people with ongoing pain have in performing activities while in pain.
Scores can range from 0 - 60 and is done by simple addition.
High PSEQ scores are strongly associated with clinically-significant functional levels and provide a useful gauge for evaluating outcomes in chronic pain patients.
Higher scores (and a higher percentile) represent lower confidence to function with pain.
|
Pre-intervention, End of intervention (6 weeks), 3 months post-intervention
|
|
Preliminary effect of the Functional Restoration Program to restore physical function (ADL)
Time Frame: Pre-intervention, End of intervention (6 weeks), 3 months post-intervention
|
Activities of Daily Living (ADL): Medical Outcomes Study [MOS] subscale, Measures limitations in physical function activities, ranging from bathing and dressing to running.
|
Pre-intervention, End of intervention (6 weeks), 3 months post-intervention
|
|
Preliminary effect of the Functional Restoration Program to restore physical function (OARS)
Time Frame: Pre-intervention, End of intervention (6weeks), 3 months post-intervention
|
Instrumental Activities of Daily Living (iADL): Older American Resources and Services [OARS] subscale, Measures ability to complete activities required to maintain independence, ranging from making telephone calls to money management.
|
Pre-intervention, End of intervention (6weeks), 3 months post-intervention
|
|
Preliminary effect of the Functional Restoration Program to restore physical function (6MWT)
Time Frame: Pre-intervention, End of intervention (6 weeks), 3 months post-intervention
|
Six minutes walk test (6MWT): The 6-min walk test is a submaximal exercise test that entails the measurement of distance (meter) walked over a span of 6 minutes.
|
Pre-intervention, End of intervention (6 weeks), 3 months post-intervention
|
|
Preliminary effect of the Functional Restoration Program to restore physical function (10mWT)
Time Frame: Pre-intervention, End of intervention (6 weeks), 3 months post-intervention
|
Ten meter walking test (10mWT): The 10 Meter Walk Test is a performance measure used to assess walking speed in meters per second over a short distance.
|
Pre-intervention, End of intervention (6 weeks), 3 months post-intervention
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Heather N Bitar, City of Hope Medical Center
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 19530 (Other Identifier: City of Hope Comprehensive Cancer Center)
- P30CA033572 (U.S. NIH Grant/Contract)
- NCI-2021-02052 (Registry Identifier: CTRP (Clinical Trial Reporting Program))
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Hematopoietic and Lymphoid Cell Neoplasm
-
University of California, San FranciscoLazarex Cancer FoundationTerminatedHematopoietic and Lymphoid Cell Neoplasm | Malignant NeoplasmUnited States
-
Hayley ThompsonNational Cancer Institute (NCI)RecruitingHematopoietic and Lymphoid Cell Neoplasm | Malignant Solid NeoplasmUnited States
-
Thomas Jefferson UniversityCompletedHematopoietic and Lymphoid Cell Neoplasm | Malignant Solid NeoplasmUnited States
-
M.D. Anderson Cancer CenterWithdrawnHematopoietic and Lymphoid Cell Neoplasm | Malignant Solid NeoplasmUnited States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)CompletedHematopoietic and Lymphoid Cell Neoplasm | Malignant Solid NeoplasmUnited States
-
M.D. Anderson Cancer CenterCompletedHematopoietic and Lymphoid Cell Neoplasm | Malignant Solid NeoplasmUnited States
-
M.D. Anderson Cancer CenterTerminatedHematopoietic and Lymphoid Cell Neoplasm | Malignant Solid NeoplasmUnited States
-
Thomas Jefferson UniversityWithdrawnHematopoietic and Lymphoid Cell Neoplasm | Malignant Solid NeoplasmUnited States
-
Fred Hutchinson Cancer CenterNational Cancer Institute (NCI)TerminatedHematopoietic and Lymphoid Cell Neoplasm | Malignant Solid NeoplasmUnited States
-
City of Hope Medical CenterNational Cancer Institute (NCI)WithdrawnHematopoietic and Lymphoid Cell Neoplasm | Malignant Solid Neoplasm
Clinical Trials on Questionnaire Administration
-
Fondazione Don Carlo Gnocchi OnlusCompleted
-
Centre Oscar LambretCentre Hospitalier Universitaire de BesanconTerminated
-
Istanbul Aydın UniversityCompleted
-
Rutgers, The State University of New JerseyNational Cancer Institute (NCI)TerminatedHealth Status UnknownUnited States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)CompletedBreast Carcinoma | Fallopian Tube Carcinoma | Endometrial Carcinoma | Ovarian Carcinoma | Primary Peritoneal Carcinoma | Deleterious CDH1 Gene Mutation | Deleterious DICER1 Gene Mutation | Deleterious SMARCA4 Gene Mutation | Deleterious STK11 Gene MutationUnited States
-
Université Catholique de LouvainRecruiting
-
M.D. Anderson Cancer CenterRecruitingHematopoietic and Lymphoid Cell Neoplasm | Malignant Solid NeoplasmUnited States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)RecruitingCOVID-19 InfectionUnited States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)Active, not recruitingEndometrial Carcinoma | Malignant Uterine Neoplasm | Uterine Corpus Cancer | Uterine Corpus SarcomaUnited States
-
Ohio State University Comprehensive Cancer CenterNational Center for Complementary and Integrative Health (NCCIH)CompletedBreast Cancer | Prostate CancerUnited States